hotspot -WSS

hotspot

author：explore 2025-08-24 04:06:57 - browse：17376

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

explore

WSS

Readout LOUD podcast: mifepristone case, GLP

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Congress considering partial increase for doctor pay in Medicare

Tome Biosciences co

Food as medicine: Medically tailored meals may get standardized

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Walensky prepares to leave CDC — and Congress — behind

Resistance to opioid

Wildfire smoke exposes gaps in outdoor worker protections

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Anesthesiologist group: stop taking Ozempic before surgery

Abortion pill case raises question: who can sue the FDA?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Abbott's new heart device gets FDA advisory panel nod

Supreme Court strikes down use of affirmative action

FDA's naming rule on biosimilars has undermined competition

Wikipedia

Covid vaccine financial winners and losers, from Pfizer to Novavax

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Having children helps parents live longer, especially after age 80

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Patient advocates debate FDA's accelerated approval process

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

explore

leisure time

knowledge

focus